CN100473664C - 多价淋巴毒素β受体激动剂及其治疗用途 - Google Patents

多价淋巴毒素β受体激动剂及其治疗用途 Download PDF

Info

Publication number
CN100473664C
CN100473664C CNB2003801090429A CN200380109042A CN100473664C CN 100473664 C CN100473664 C CN 100473664C CN B2003801090429 A CNB2003801090429 A CN B2003801090429A CN 200380109042 A CN200380109042 A CN 200380109042A CN 100473664 C CN100473664 C CN 100473664C
Authority
CN
China
Prior art keywords
antibody
hucbe11
antigen recognition
specific
multivalent antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801090429A
Other languages
English (en)
Chinese (zh)
Other versions
CN1798765A (zh
Inventor
E·加伯
V·贝利
J·L·布朗宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1798765A publication Critical patent/CN1798765A/zh
Application granted granted Critical
Publication of CN100473664C publication Critical patent/CN100473664C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB2003801090429A 2002-12-20 2003-12-22 多价淋巴毒素β受体激动剂及其治疗用途 Expired - Fee Related CN100473664C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515402P 2002-12-20 2002-12-20
US60/435,154 2002-12-20

Publications (2)

Publication Number Publication Date
CN1798765A CN1798765A (zh) 2006-07-05
CN100473664C true CN100473664C (zh) 2009-04-01

Family

ID=32682169

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801090429A Expired - Fee Related CN100473664C (zh) 2002-12-20 2003-12-22 多价淋巴毒素β受体激动剂及其治疗用途

Country Status (8)

Country Link
US (1) US20060104971A1 (enExample)
EP (1) EP1583503A4 (enExample)
JP (1) JP2006515750A (enExample)
CN (1) CN100473664C (enExample)
AU (1) AU2003299984A1 (enExample)
CA (1) CA2511013A1 (enExample)
NO (1) NO20053530L (enExample)
WO (1) WO2004058191A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
TR200602095T2 (tr) * 2000-10-13 2007-02-21 Biogen Idec Ma Inc. Hümanize Anti-LT-Beta-R antikorları
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SG10201403526YA (en) 2005-07-25 2014-10-30 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
AU2016231617B2 (en) * 2006-06-12 2018-08-23 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2007257692B2 (en) * 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2014200661B2 (en) * 2006-06-12 2016-06-30 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR100967623B1 (ko) * 2008-02-22 2010-07-05 전남대학교산학협력단 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies
WO2014118578A1 (en) * 2013-02-04 2014-08-07 University Of Huddersfield Composition comprising a tnfr agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma.
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
WO2020081841A1 (en) 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
WO2021116337A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
WO1996022788A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669941A (en) * 1898-12-17 1901-03-12 Electric Axle Light & Power Company Electric switch.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
SI2857516T1 (sl) * 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
ATE463745T1 (de) * 2000-06-30 2010-04-15 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
JP2004520810A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
TR200602095T2 (tr) * 2000-10-13 2007-02-21 Biogen Idec Ma Inc. Hümanize Anti-LT-Beta-R antikorları
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7576185B2 (en) * 2002-03-05 2009-08-18 Genentech, Inc. PRO34128 antibodies
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
WO1996022788A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Characterization of surface lymphotoxin forms. Use ofspecific monoclonal antibodies and soluble receptors. BROWNING ET AL.JOURNAL OF IMMUNOLOG,Vol.154 No.1. 1995
Characterization of surface lymphotoxin forms. Use ofspecific monoclonal antibodies and soluble receptors. BROWNING ET AL.JOURNAL OF IMMUNOLOG,Vol.154 No.1. 1995 *

Also Published As

Publication number Publication date
CA2511013A1 (en) 2004-07-15
EP1583503A2 (en) 2005-10-12
US20060104971A1 (en) 2006-05-18
CN1798765A (zh) 2006-07-05
EP1583503A4 (en) 2006-08-09
WO2004058191A3 (en) 2005-12-29
AU2003299984A1 (en) 2004-07-22
NO20053530L (no) 2005-09-20
WO2004058191A2 (en) 2004-07-15
NO20053530D0 (no) 2005-07-19
JP2006515750A (ja) 2006-06-08

Similar Documents

Publication Publication Date Title
CN100473664C (zh) 多价淋巴毒素β受体激动剂及其治疗用途
JP7726967B2 (ja) 多重特異性結合タンパク質及びその改善
CN112368012B (zh) 靶向nkg2d受体的抗体可变结构域
CN102397542B (zh) 抗血管内皮生长因子受体-1的抗体
KR101463098B1 (ko) ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
JP2007530588A (ja) レセプターカップリング剤およびその治療用途
CN101479296A (zh) Trail受体结合剂和其用途
US20060134102A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
JP2006515750A5 (enExample)
KR20150013321A (ko) Ｃｄ33 항체 및 암을 치료하기 위한 이의 용도
JP2012207036A (ja) 血管内皮増殖因子に対する抗体と、２型ヒト上皮成長因子受容体に対する抗体を用いた腫瘍治療
JP2006513225A5 (enExample)
TWI879889B (zh) 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途
US20090175866A1 (en) Treatment of b-cell malignancies
US20250090659A1 (en) Combination therapy with an anti-cd19 antibody and parsaclisib
CA3195058A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN112439060B (zh) Pd-l1免疫疗法的新用途
RU2788531C2 (ru) Белок, связывающийся с nkg2d, cd16 и с опухолеспецифическим антигеном
EP2236139A1 (en) Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
MXPA06010891A (en) Receptor coupling agents and therapeutic uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090401

Termination date: 20100122